StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.81 | $1.94 | +7.18% | 2.8M |
| 05-12 | $1.94 | $1.92 | -1.03% | 1.8M |
| 05-13 | $1.92 | $1.87 | -2.60% | 1.9M |
| 05-14 | $1.87 | $1.81 | -3.21% | 1.2M |
| 05-15 | $1.80 | $1.83 | +1.67% | 1.8M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Metric | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-14.86M | $-11.48M | $-7.88M | $-3.67M |
Net Income | $-14.44M | $-11.09M | $-7.61M | $-3.53M |
EPS (Diluted) | $-10.19 | $-9.50 | $-7.60 | $-4.59 |
Total Assets | $10.88M | $9.34M | $12.87M | $12.65M |
Total Liabilities | $3.39M | $2.73M | $2.92M | $2.59M |
Cash & Equivalents | $9.82M | $8.04M | $11.35M | $11.28M |
Free Cash Flow OCF − CapEx | $-12.19M | $-9.81M | $-6.68M | Not available |
Shares Outstanding | 2.77M | 1.20M | 966.35K | 851.30K |